Overview

The Role of Montelukast in Rhinitis and Sleep

Status:
Completed

Trial end date:
2009-01-01

Target enrollment:

Participant gender:

Summary

The hypothesis is that a leukotriene receptor antagonist (LRA), montelukast, will decrease nasal congestion leading to increased patency of the nose and a decrease in nighttime sleep fragmentation in individuals with year round allergic rhinitis or perennial allergic rhinitis (PAR). This decrease in sleep fragmentation will reduce daytime somnolence and fatigue.

Phase:

Phase 4

Details

Lead Sponsor:

Penn State University

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Montelukast